Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02045446 |
Recruitment Status :
Active, not recruiting
First Posted : January 24, 2014
Last Update Posted : August 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stage IV Non-Small Cell Lung Cancer | Radiation: Stereotactic Body Radiation Therapy Drug: Maintenance chemotherapy | Phase 2 |
This protocol is a randomized phase II trial of maintenance chemotherapy versus consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy for patients with Stage IV non-small cell lung cancer (NSCLC).
Prior to accrual on the trial, patients with Stage IV NSCLC will be treated with standard first-line chemotherapy. Patients who achieve a partial response or stable disease by imaging criteria with fewer than or equal to six sites of oligometastatic disease will be randomized to maintenance chemotherapy or consolidative SBRT to all sites of disease (followed by maintenance chemotherapy at the medical oncologist's discretion). Choices of first line and maintenance chemotherapy will be determined by the medical oncologist based on clinical appropriateness.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 29 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial |
Actual Study Start Date : | February 2014 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Maintenance chemotherapy
FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
|
Drug: Maintenance chemotherapy
Maintenance chemotherapy |
Experimental: Stereotactic Body Radiation Therapy
consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
|
Radiation: Stereotactic Body Radiation Therapy
Other Name: SBRT Drug: Maintenance chemotherapy Maintenance chemotherapy |
- Progression free survival [ Time Frame: 5 years ]Evaluate the effect of SBRT with or without maintenance chemotherapy versus maintenance chemotherapy alone on progression free survival
- Actuarial rate in-field local control [ Time Frame: 5 years ]To describe the actuarial rate in-field local control and rate of out-of-field disease progression
- Toxicities [ Time Frame: 2 years ]To evaluate the safety of SBRT with metastatic NSCLC after prior chemotherapy
- Overall survival [ Time Frame: 5 years ]To evaluate overall survival after SBRT followed by maintenance chemotherapy in comparison to maintenance chemotherapy alone.
- Duration of maintenance chemotherapy [ Time Frame: 5 years ]To evaluate the duration of maintenance chemotherapy and time to initiation of third line systemic agent (chemotherapy or biologic agent)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have biopsy proven metastatic NSCLC (Stage IV).
- Patients must have received first line chemotherapy, from 4-6 cycles, and achieved stable disease or a partial response.
- Patients receiving first-line erlotinib, gefitinib, or crizotinib for EGFR mutant-positive or EML4-ALK positive NSCLC will be excluded.
- Age ≥ 18 years
- Patients must have measurable disease at baseline.
-
Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver and ≤3 in the lung) identified by PET scan and also seen on correlative plain film, CT scan, or MRI within 8 weeks prior to the initiation of SBRT.
- For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months
- Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months.
- Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply.
- Up to 2 contiguous vertebral metastases will be considered a single site of disease.
- Patients must have a KPS >60
- AST, ALT & Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total bilirubin must be within the limit of normal.
- Patients should have adequate bone marrow function as defined by peripheral granulocyte count of ≥1500/mm³.
- Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN).
- Females of childbearing potential should have a negative pregnancy test.
- Patients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) ≥ 1L.
- Patients must provide verbal and written informed consent to participate in the study.
- Total bilirubin: within normal institutional limits
Exclusion Criteria:
- Patients who previously received radiotherapy to the primary site with CT evidence of disease progression at the primary site within 3 months following the initial radiotherapy.
- Patients with either untreated brain metastases or brain metastases treated within the past three months are ineligible
- Patients with serious, uncontrolled, concurrent infection(s).
- Significant weight loss (>10%) in the prior 3 months.
- Because the tolerance dose of SBRT to the gastrointestinal tract is not established, patients with metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes will not be eligible.
- Patients with cutaneous metastasis of NSCLC.
- Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cancers.
- Patients with more than 6 discrete extra-cranial lesions.
- Participation in any investigational drug study within 4 weeks preceding the start of study treatment.
- Unwillingness to participate or inability to comply with the protocol for the duration of the study.
- Patients who are pregnant. Patients with reproductive capability will need to use adequate contraception during the time of participation in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02045446
United States, Texas | |
UT Southwestern Medical Center | |
Dallas, Texas, United States, 75235 |
Principal Investigator: | Puneeth Iyengar, MD | UTSW |
Documents provided by University of Texas Southwestern Medical Center:
Responsible Party: | University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT02045446 |
Other Study ID Numbers: |
STU 092013-070 |
First Posted: | January 24, 2014 Key Record Dates |
Last Update Posted: | August 13, 2020 |
Last Verified: | July 2020 |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |